Eledon Pharmaceuticals, Inc. Common Stock (ELDN) is a publicly traded Healthcare sector company. As of July 8, 2026, ELDN trades at $3.97 with a market cap of $306.44M and a P/E ratio of -7.63. ELDN moved +1.53% today. Year to date, ELDN is +160.26%; over the trailing twelve months it is +26.37%. Its 52-week range spans $1.35 to $5.08. Analyst consensus is strong buy with an average price target of $8.67. Rallies surfaces ELDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eledon Trial Achieves 100% Insulin Independence in Tegoprubart Islet-Transplant Study: Eledon Pharmaceuticals reported that all evaluable patients in its islet-transplant trial combining tegoprubart with donor islets achieved insulin independence, demonstrating a 100% success rate. The result positions Eledon ahead in the cell therapy field as rivals like Avaí Bio finalize a GMP Master Cell Bank for their alpha-Klotho program.
| Metric | Value |
|---|---|
| Price | $3.97 |
| Market Cap | $306.44M |
| P/E Ratio | -7.63 |
| EPS | $-0.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.08 |
| 52-Week Low | $1.35 |
| Volume | 818.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-45.62M |
| Gross Margin | 0.00% |
3 analysts cover ELDN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.67.